GnRH receptor super-agonist. Continuous receptor activation downregulates GnRH receptors after initial flare, suppressing LH/FSH.
Reference facts
- Also known as
- Lupron, Eligard
- Category
- GnRH & Reproductive
- Mechanism of action
- GnRH receptor super-agonist. Continuous receptor activation downregulates GnRH receptors after initial flare, suppressing LH/FSH.
- Targets
- GnRH receptor
- Indications under research or approved
- Prostate cancer, Endometriosis, Uterine fibroids, Central precocious puberty
- Regulatory status (reference entry)
- FDA-approved (1985)
- Half-life
- ~3 hours (depot formulations release over 1-6 months)
- Sequence notes
- Nonapeptide pyroGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt — D-Leu at position 6 and ethylamide replace native Gly10.
- Molecular weight (Da)
- 1209
- Originator / sponsor
- AbbVie / Tolmar
- First reported
- 1973
Primary References
Explore research articles about Leuprolide
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.